Comorbidities in Type 2 Diabetes Mellitus

Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, Egypt

Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes
• Intervention / Treatment: Diagnostic test: HBA1C; Diagnostic test: Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides; Diagnostic test: Urine analysis and urinary albumin-to-creatinine ratio; Diagnostic test: Serum creatinine and estimated glomerular filtration rate; Diagnostic test: Complete blood count; Diagnostic test: Thyroid-stimulating hormone; Diagnostic test: Serum iron, TIBC, Transferrin saturation and serum ferritin if needed; Procedure: Electrocardiography (ECG); Procedure: Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound; Procedure: Arterial duplex ultrasound of both lower limbs; Diagnostic test: Random blood glucose; Diagnostic test: AST, ALT, albumin

Detailed Description

All-cause mortality rates have declined substantially in several high-income countries, including England.

A diversification in non-fatal conditions in people with DM has also been reported. This is attributable to broader, non-vascular conditions. Due to increasing longevity among people with type 2 DM with increasing and diversifying multimorbidity in them, the health needs of people with Type 2 DM are therefore likely to be broad, and complex.

Finding multimorbidity (two or more chronic conditions) is common in people with Type 2 DM and increasing, but the comorbidity profiles of people with T2DM vary substantially.

Many studies have primarily focused on identifying multimorbidity patterns in the general population.

The understanding of multimorbidity patterns and composition of specific comorbidities in people with DM, and how this varies across patient groups and during the course of the disease, is limited. Further knowledge of this could provide insight into providing more holistic and more personal approaches to clinical guideline development, care pathways, and secondary prevention.

• Study Type: Interventional
• Enrollment (Actual): 295
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Egypt
  • Kharga Oasis
    • Al Khārjah, Kharga Oasis, Egypt, 72511
      • New Valley University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with type 2 diabetes.

Exclusion Criteria:

1. Patients with type 1 diabetes.
2. Patients with secondary diabetes.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: type 2 DM

Diagnostic test: HBA1C; blood sample on EDTA; Diagnostic test: Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides; serum sample; Diagnostic test: Urine analysis and urinary albumin-to-creatinine ratio; Morning urine sample; Diagnostic test: Serum creatinine and estimated glomerular filtration rate; serum sample; Diagnostic test: Complete blood count; blood sample on EDTA; Diagnostic test: Thyroid-stimulating hormone; serum sample; Diagnostic test: Serum iron, TIBC, Transferrin saturation and serum ferritin if needed; serum sample; Procedure: Electrocardiography (ECG); by electrocardiogram; Procedure: Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound; imaging; Procedure: Arterial duplex ultrasound of both lower limbs; imaging; Diagnostic test: Random blood glucose; serum sample; Diagnostic test: AST, ALT, albumin; serum sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of participants with hypertension	At time of inclusion in the study
Number of participants with dyslipidemia	At time of inclusion in the study
Number of participants with thyroid disorder	At time of inclusion in the study
Number of participants with Diabetic kidney disease	At time of inclusion in the study
Number of participants with Coronary heart disease	At time of inclusion in the study
Number of participants with Stroke	At time of inclusion in the study
Number of participants with Peripheral arterial disease	At time of inclusion in the study
Number of participants with Diabetic eye disease	At time of inclusion in the study
Number of participants with Peripheral neuropathy	At time of inclusion in the study
Number of participants with Liver disease	At time of inclusion in the study
Number of participants with Infections	At time of inclusion in the study
Number of participants with Cancer	At time of inclusion in the study

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of participants with controlled diabetes mellitus with correlation to the number of cormobidity	At time of inclusion in the study
Correlate the presence of each co-morbidity with the extent of diabetes control	At time of inclusion in the study

Collaborators and Investigators

• Sponsor: New Valley University

Publications and helpful links

General Publications

• Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10.
• Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, Imperatore G. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet. 2018 Jun 16;391(10138):2430-2440. doi: 10.1016/S0140-6736(18)30314-3. Epub 2018 May 18.
• Harding JL, Shaw JE, Peeters A, Davidson S, Magliano DJ. Age-Specific Trends From 2000-2011 in All-Cause and Cause-Specific Mortality in Type 1 and Type 2 Diabetes: A Cohort Study of More Than One Million People. Diabetes Care. 2016 Jun;39(6):1018-26. doi: 10.2337/dc15-2308. Epub 2016 Apr 26.
• Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, Gregg EW. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021 Mar;9(3):165-173. doi: 10.1016/S2213-8587(20)30431-9. Epub 2021 Feb 4.

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2023
• Primary Completion (Actual): December 30, 2025
• Study Completion (Actual): February 15, 2026

Study Registration Dates

• First Submitted: March 30, 2023
• First Submitted That Met QC Criteria: May 16, 2023
• First Posted (Actual): May 24, 2023

Study Record Updates

• Last Update Posted (Actual): May 26, 2026
• Last Update Submitted That Met QC Criteria: May 21, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 2; Investigative Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Cell Count; Cytological Techniques; Hematologic Tests; Cell Physiological Phenomena; Blood Physiological Phenomena; Circulatory and Respiratory Physiological Phenomena; Diagnostic Techniques, Urological; Clinical Chemistry Tests; Blood Cell Count; Urinalysis
• Other Study ID Numbers: CODM2KNV

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No